Active Biotech AB Share Price Xetra
Equities
BTPC
SE0001137985
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
22/05 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
22/05 | Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology | CI |
Sales 2024 * | - | Sales 2025 * | 1.56Cr 14.74L 13.75L 12Cr | Capitalization | 18Cr 1.67Cr 1.56Cr 139.56Cr |
---|---|---|---|---|---|
Net income 2024 * | -4.2Cr -39.69L -37.02L -33Cr | Net income 2025 * | -3.5Cr -33.08L -30.85L -28Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 11.4 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.39% |
Managers | Title | Age | Since |
---|---|---|---|
Helén Tuvesson
CEO | Chief Executive Officer | 62 | 01/98/01 |
Hans Kolam
DFI | Director of Finance/CFO | 73 | 01/00/01 |
Erik Vahtola
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
BRD | Director/Board Member | 74 | 23/19/23 |
Director/Board Member | 50 | 01/20/01 | |
Michael Shalmi
CHM | Chairman | 59 | 23/19/23 |
1st Jan change | Capi. | |
---|---|---|
+17.08% | 12TCr | |
+21.03% | 12TCr | |
+20.96% | 2.66TCr | |
-22.56% | 1.99TCr | |
-17.22% | 1.63TCr | |
-44.74% | 1.55TCr | |
-19.30% | 1.55TCr | |
+58.97% | 1.48TCr | |
+2.08% | 1.37TCr |
- Stock Market
- Equities
- ACTI Stock
- BTPC Stock